Research compendium
Cagrilintide
Cagrilintide is an amylin analog developed through peptide modification and lipidation. Its documentation separately addresses molecular design, receptor interaction and clinical outcomes. The individual entity must also be distinguished from experimental combinations.
This is a research reference, not a product offered in the Asciende catalog. Published studies do not establish the identity, purity or availability of a commercial preparation.
What is established and what remains a hypothesis
Keep source limits and editorial status visible. A proposed mechanism should not be presented as a confirmed property in every context.
- Is the source the original work, a review or a later interpretation?
- Has the observation been reproduced under independent conditions?
- Does the material defined in the paper match the entity named in this entry?
Mechanism described in the literature
Reconstructed receptor complexes have been used to study cagrilintide binding to amylin receptors and the calcitonin receptor. These models reveal molecular recognition without quantifying each receptor’s contribution to a clinical response.
Classification
Lipidated peptide amylin analog
Other names
- Cagrilintide
Molecular design and physical behavior
Development work sought a long-acting analog and addressed amylin’s tendency to form fibrils. This identifies a design problem without certifying stability for every preparation named cagrilintide. Formulation and tested conditions remain separate information.
What observing the receptor contributes
The structural study examined complexes with different amylin receptors and the calcitonin receptor. Its value lies in comparing contacts and dynamics within those systems. Treating a structure as direct proof of a whole-body effect skips several evidence levels.
The individual entity in clinical research
In the phase 2 trial of adults with overweight or obesity without diabetes, cagrilintide showed weight differences versus placebo over twenty-six weeks, with gastrointestinal events also recorded. This individual-entity study does not establish outcomes for a semaglutide combination.
Questions and answers
Is cagrilintide a GLP-1 agonist?
It is not classified that way. The cited evidence concerns an amylin analog studied at amylin and calcitonin receptors.
Are cagrilintide and CagriSema the same?
No. CagriSema names the combination of cagrilintide and semaglutide; evidence must not automatically transfer between them.
Sources
- Development of Cagrilintide, a Long-Acting Amylin Analogue — J Med Chem (2021); PMID 34288673; DOI 10.1021/acs.jmedchem.1c00565
- Development of Cagrilintide, a Long-Acting Amylin Analogue — J Med Chem (2021); PMID 34288673; DOI 10.1021/acs.jmedchem.1c00565
- Structural and dynamic features of cagrilintide binding to calcitonin and amylin receptors — Nat Commun (2025); PMID 40204768; DOI 10.1038/s41467-025-58680-y
- Structural and dynamic features of cagrilintide binding to calcitonin and amylin receptors — Nat Commun (2025); PMID 40204768; DOI 10.1038/s41467-025-58680-y
- Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial — Lancet (2021); PMID 34798060; DOI 10.1016/S0140-6736(21)01751-7
- Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial — Lancet (2021); PMID 34798060; DOI 10.1016/S0140-6736(21)01751-7